Matthew Kolek, MD

Primary Specialties:
  • Cardiology  (Board Certified)
  • Cardiac Electrophysiology  (Board Certified)
Accepting New Patients
  • Education

    Education

    Medical School:

    University of Utah School of Medicine, Salt Lake City, UT

    Residency:

    Vanderbilt University Medical Center, Nashville, TN

    Fellowship:

    Vanderbilt University Medical Center, Nashville, TN

    Board Certification:

    American Board of Internal Medicine -- Cardiovascular Disease; American Board of Internal Medicine -- Internal Medicine

    Awards

    University of Utah School of Medicine Dean’s Award for Best Medical Student, 05/2008;
    Alpha Omega Alpha Honor Society, 10/2007

  • Research & Publications

    Research & Publications

    <p>RESEARCH SUPPORT</p> <p>VR5716 (CTSA UL1TR000445) Kolek (PI) 02/20/13–06/30/16 Genetically Determined Response to Atenolol in Patients with Persistent Atrial Fibrillation</p> <p>The goal of this study was to test the hypothesis that polymorphisms in candidate beta-adrenergic signaling genes are associated with response to beta-blocker therapy in subjects with persistent/permanent atrial fibrillation. Role: PI</p> <p>American Heart Association 13CRP16960108 Kolek (PI) 07/01/13–06/30/16 Genetically Determined Response to Atenolol in Patients with Persistent Atrial Fibrillation</p> <p>The goal of this study was to test the hypothesis that polymorphisms in beta-adrenergic signaling genes and polymorphisms associated with PR interval in genome-wide association studies are associated with response to beta-blocker therapy in subjects with persistent/permanent atrial fibrillation. Role: PI</p> <p>VR9644 (CTSA UL1TR000445) Kolek (PI) 07/03/14–06/30/16 A Pilot and Feasibility Study to Determine If a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs</p> <p>The goal of this studywas to gather pilot data for a larger study that will ultimately test the hypothesis that chromosome 4q24 variants modulate the response to antiarrhythmic drug therapy in subjects with symptomatic atrial fibrillation. Role: PI</p> <p><strong>PUBLICATIONS AND PRESENTATIONS</strong></p> <p><u>Publications</u></p> <ol> <li> <strong>Kolek MJ</strong>, Graves AJ, Meng Xu M, Bian A, Teixeira PL, Shoemaker MB, Parvez B, Xu H, Heckbert SR, Ellinor PT, Benjamin EJ, Alonso A, Denny JC, Moons KGM, Shintani AK, Harrell FE, Roden DM, Darbar D. Evaluation of a Prediction Model for the Development of Atrial Fibrillation in a Repository of Electronic Medical Records. JAMA Cardiol 2016; Published online Oct. 12. </li> <li> <strong>Kolek MJ</strong><strong>, </strong>Patel NJ, Clair WK, Whalen SP, Rottman JN, Kanagasundram A, Shen ST, Saavedra PJ, Estrada JC, Abraham RL, Ellis CR. Efficacy of a Bio-Absorbable Antibacterial Envelope to Prevent Cardiac Implantable Electronic Device Infections in High-Risk Subjects. J Cardiovasc Electrophysiol 2015;26:1111-1116. </li> <li> <strong>Kolek MJ</strong>, Muehlschlegel JD, Bush WS, Parvez B, Murray KT, Stein CM, Shoemaker MB, Blair MA, Kor KC, Roden DM, Donahue BS, Fox AA, Shernan SK, Collard CD, Body SC, Darbar D. Genetic and clinical risk prediction model for postoperative atrial fibrillation. Circ Arrhythm Electrophysiol 2015;8:25-31. </li> <li> Balouch MA, <strong>Kolek MJ</strong>, Darbar D. Improved understanding of the pathophysiology of atrial fibrillation through the lens of discrete pathological pathways. Glob Cardiol Sci Pract 2014;Jan:24-36. </li> <li> <strong>Kolek MJ</strong>, Edwards TL, Muhammad R, Balouch A, Shoemaker MB, Blair MA, Kor KC, Takahashi A, Kubo M, Roden DM, Tanaka T, Darbar D. A Genome-Wide Association Study to Identify Genomic Modulators of Rate Control Therapy in Patients with Atrial Fibrillation. Am J Cardiol 2014;114:593-600. </li> <li> <strong>Kolek MJ</strong>, Parvez B, Muhammad R, Shoemaker MB, Blair MA, Stubblefield T, Kucera GA, Denny JC, Roden DM, Darbar D. <a href="http://www.ncbi.nlm.nih.gov/pubmed/24161141">A Common Variant on Chromosome 4q25 is Associated With Prolonged PR Interval in Subjects With and Without Atrial Fibrillation.</a> Am J Cardiol 2014;113:309-13. </li> <li> Richardson TD, <strong>Kolek MJ</strong>, Goyal SK, Shoemaker MB, Lewis AA, Rottman JN, Whalen SP, Ellis CR. <a href="http://www.ncbi.nlm.nih.gov/pubmed/24028661">Comparative outcomes of transvenous extraction of sprint fidelis and riata defibrillator leads: a single center experience.</a> J Cardiovasc Electrophysiol. 2014;25:36-42. </li> <li> <strong>Kolek MJ</strong>, Dresen WF, Wells QS, Ellis CR. Use of an Antibacterial Envelope is Associated with Reduced Cardiac Implantable Electronic Device Infections in High-Risk Patients. Pacing Clin Electrophysiol 2013;36:354-61. </li> <li> Ellis CR, <strong>Kolek MJ</strong>. Rising infection rate in cardiac electronic device implantation; the role of the AIGISRx® antibacterial envelope in prophylaxis. <em>Comb Prod Ther</em>. 2011;1:1–9. </li> <li> Anderson JL, Horne BD, <strong>Kolek MJ</strong>, Muhlestein JB, Mower CP, Park JJ, May HT, Camp NJ, Carlquist JF. Genetic variation at the 9p21 locus predicts angiographic coronary artery disease prevalence but not extent and has clinical utility. Am Heart J 2008;156:1155-62. </li> <li> Rondida MT, Lappé JM, Carlquist JF, Muhlestein JB, <strong>Kolek MJ</strong>, Horne BD, Pearson RR, Anderson JL. Soluble CD40 ligand as a predictor of coronary artery disease and long-term clinical outcomes in stable patients undergoing coronary angiography. Cardiology 2008;109:196-201. </li> <li> Horne BD, Camp NJ, Carlquist JF, Muhlestein JB, <strong>Kolek MJ</strong>, Nicholas ZP, Anderson JL. Multiple-polymorphism associations of seven matrix metalloproteinase and tissue inhibitor metalloproteinase genes with myocardial infarction and angiographic coronary artery disease. Am Heart J 2007;154:751-8. </li> <li> Horne BD, Camp NJ, Anderson JL, Mower CP, Clarke JL, <strong>Kolek MJ</strong>, Carlquist JF. Multiple less common genetic variants explain the association of the cholesteryl ester transfer protein gene with coronary artery disease. J Am Coll Cardiol 2007;49:2053-60. </li> <li> Carlquist JF, Horne BD, Muhlestein JB, Lappe DL, Whiting BM, <strong>Kolek MJ</strong>, James BC, Anderson JL. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis 2006;22:191-197. </li> <li> May HT, Horne BD, Anderson JL, Wolfert RL, Muhlestein JB, Renlund DG, Clarke JL, <strong>Kolek MJ</strong>, Bair TL, Pearson RR, Sudhir K, Carlquist JF. Lipoprotein-associated phospholipase A<sub>2</sub> independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J 2006;152:997-1003. </li> <li> Horne BD, Carlquist JF, Cannon-Albright LA, Muhlestein JB, McKinney JT, <strong>Kolek MJ</strong>, Clarke JL, Anderson JL, Camp NJ. High-resolution characterization of linkage disequilibrium structure and selection of tagging single nucleotide polymorphisms: application to the cholesteryl ester transfer protein gene. Ann Hum Genet 2006;70:524-34 </li> <li>Kolek MJ, Carlquist JF, Thaneemit-Chen S, Whiting BM, Horne BD, Muhlestein JB, Lavori P, Anderson JL. The role of a common adenosine monophosphate deaminase (AMPD)-1 polymorphism in outcomes of ischemic and nonischemic heart failure. J Card Fail 2005;11:677-83</li> <li>Clarke JL, Anderson JL, Carlquist JF, Roberts RF, Horne BD, Bair TL, Kolek MJ, Mower CP, Crane AM, Roberts WL, Muhlestein JB. Comparison of differing C-reactive protein assay methods and their impact on cardiovascular risk assessment. Am J Cardiol 2005;95:155-158.</li> <li>Kolek MJ, Carlquist JF, Muhlestein JB, Whiting BM, Horne BD, Anderson JL. The toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J 2004;148:1034-1040.</li> </ol> <p><strong>Presentations</strong></p> <ul> <li> Southeast Electrophysiology Fellows Summit, 02/2016 <ul> <li>Venous occlusion in a patient with RV lead failure</li> </ul> </li> <li> Vanderbilt Cardiovascular Research Seminar, 04/2015 <ul> <li>Personalizing treatment for atrial fibrillation</li> </ul> </li> <li> American Heart Association Scientific Sessions, 11/2014 <ul> <li>Comprehensive evaluation of QT interval during abrupt changes in heart rate and associated neurohormonal and inflammatory markers</li> <li>External validation of a prediction model for the development of atrial fibrillation in a repository of electronic medical records</li> </ul> </li> <li> Vanderbilt Cardiovascular Research Seminar, 01/2014 <ul> <li>Unraveling the pathophysiology of and improving treatment for atrial fibrillation</li> </ul> </li> <li> American Heart Association Scientific Sessions, 11/2013 <ul> <li>A combined genetic and clinical risk prediction model for postoperative atrial fibrillation</li> </ul> </li> <li> Vanderbilt University Cardiology Grand Rounds, 04/2013 <ul> <li>Genetic basis of AF: converging pathways or parallel mechanisms?</li> </ul> </li> <li> American College of Cardiology Scientific Sessions, 04/2012 <ul> <li>Reduced cardiac rhythm device related infections in high-risk patients with an implanted antibacterial envelope</li> </ul> </li> <li> American Society of Human Genetics Scientific Meeting, 06/2005 <ul> <li>The mannose binding lectin Arg52Cys gene coding variant predicts angiographic coronary artery disease</li> </ul> </li> <li> American College of Cardiology Scientific Sessions, 04/2004 <ul> <li>The role of a common adenosine monophosphate deaminase (AMPD)-1 polymorphism in outcome of ischemic and non-ischemic heart failure</li> </ul> </li> <li> American Heart Association Scientific Sessions, 11/2003 <ul> <li>Toll-like receptor 4 D299G polymorphism predicts lower risk of coronary artery disease and diabetes</li> </ul> </li> </ul>